Intellia Therapeutics (NTLA) Operating Margin (2015 - 2026)
Intellia Therapeutics (NTLA) reported Operating Margin of 668.08% for Q1 2026, up 5850.0% year-over-year from 11.23% in Q1 2025, and down 55.78% quarter-over-quarter from 428.86% in Q4 2025.
Intellia Therapeutics (NTLA) Operating Margin (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 12 years of Operating Margin data on file, last reported at 668.08% in Q1 2026.
- Operating Margin for Q1 2026 came in at 668.08%, up 5850.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 636.56% (up 55080.0% YoY), and the FY2025 annual result was 651.67%, up 27143.0% from the prior year.
- Operating Margin fell to 668.08% in Q1 2026 per NTLA's latest filing, from 428.86% in the prior quarter.
- Over five years, Operating Margin peaked at 7297.44% in Q4 2023 and troughed at 1998.61% in Q2 2024.
- A 5-year average of 452.5% and a median of 808.86% in 2025 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2022 and 2024: Operating Margin soared 2320217 bps in 2022, then tumbled 835731 bps in 2024.
- A 5-year view of Operating Margin shows it stood at 811.07% in 2022, then jumped by 1000 bps to 7297.44% in 2023, then sank by 115 bps to 1059.86% in 2024, then surged by 60 bps to 428.86% in 2025, then plunged by 56 bps to 668.08% in 2026.
- Business Quant data shows NTLA's Operating Margin at 668.08% in Q1 2026, 428.86% in Q4 2025, and 808.86% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Intellia Therapeutics | 1.86 Bn | 1.86 Bn | - | -668.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -668.08% |
| Dec 31, 2025 | -428.86% |
| Sep 30, 2025 | -808.86% |
| Jun 30, 2025 | -772.17% |
| Mar 31, 2025 | -726.57% |
| Dec 31, 2024 | -1,059.86% |
| Sep 30, 2024 | -1,588.96% |
| Jun 30, 2024 | -1,998.61% |
| Mar 31, 2024 | -394.00% |
| Dec 31, 2023 | 7,297.44% |
| Sep 30, 2023 | -1,093.29% |
| Jun 30, 2023 | -973.47% |
| Mar 31, 2023 | -888.13% |
| Dec 31, 2022 | -811.07% |
| Sep 30, 2022 | -795.49% |
| Jun 30, 2022 | -700.65% |
| Mar 31, 2022 | -1,281.96% |
| Dec 31, 2021 | -625.60% |
| Sep 30, 2021 | -23,997.67% |
| Jun 30, 2021 | -1,053.69% |